Updated MST report - target of $3.68 a share, page-99

Perthpest,

Good post. Remember what Shire Pharmaceuticals did with Orphan Drugs a few years back.

If we were Nasdaq Listed we wouldn’t be wallowing down here at $2.22. Your valuation comes out at $132 per share. Sounds crazy but we have all seen Nasdaq companies have moves like this with successful trials.

And that’s not including our 5 other indications. This isn’t like the old days when a biotech tried to cure diseases with random small molecule drugs they found in venomous animals or rainforests etc. The knowledgeable scientists progressing both our drugs have a very good idea what to expect. As Jon Pilcher just said the pre-clinical studies for 2591 have extraordinary results.

NEU is only 12 months from Ph2 results for 4 more indications. If they were to prove successful a certain value would have to be attributed to the possible success of even more indications. Is NEU currently doing pre-clinical work in more diseases. Are any any of the many companies that NEU are in discussions with, offering partnerships and money to pursue the big issues, Dementia,Autism,Parkinsons and Huntington’s ??!???

Now that the ASX market has had a taste of Nasdaq style success with Afterpay , Atalassian and others, punters will be keen for more high tech global winners. Post Ph3 results NEU will be front page of Financial Press.

I really do think many investors have a bad relationship ship with money, they are afraid of success and don’t believe they deserve to win big time. They don’t date to dream big. To my mind that’s why most people don’t get really wealthy. Most people don’t ever achieve wealth because they can’t overcome the mindset of hard work and frugality., This work is awash with money. It’s never been easier to earn immense wealth.

All an investor has to do , is trawl the stock market and find tomorrow’s winners. They are in by people with big dreams, courage and tenacity. NEU is one of those stories. 30 years of science and hard work.

The number companies that will be big winners is growing as the digital revolution keeps progressing. NEU will take part as the interconnected sufferers and caters keep abreast of our progress. It won’t take years to boost sales. We’ve got Orphan Status.

Only 12 months to go in this long journey, however our shareprice has started its climb now.